-Live Mint CERC calls for a variable ‘compensatory tariff' to be offered to Adani Power till fuel situation stabilizes In an unprecedented move, India's apex power sector regulator offered a bailout package to Adani Power Ltd in a late Tuesday order to offset losses on account of the unexpected increase in the prices of imported coal and the unavailability of domestic coal for the company's 4,620 megawatts (MW) thermal power project at...

-The Times of India A six-member CBI and income tax team has begun examining over 5,800 tapes of recorded conversations of former corporate lobbyist Niira Radia with politicians, corporate honchos and others. The team, headed by a deputy inspector general-rank officer, started going through the tapes and its transcripts running into 49 volumes last week as per the directions of the Supreme Court in February, sources said. An apex court bench comprising...

-The Times of India President Pranab Mukherjee has given his assent to the tougher anti-rape bill, bringing into force the new legislation which provides for stringent punishment for rapists and repeat offenders and makes provisions of strict punishment for offences like stalking, voyeurism, disrobing and acid attacks. Presidential assent to the Criminal Law (Amendment) Bill, 2013, came on Tuesday - just two days before the February 3 Ordinance on the issue was...

-The Business Standard CAG state audit report NCT has also unearthed a glaring lack of planning cutting across projects, sectors It may be India's capital city, but behind the New Delhi's storied corridors of power and flush coffers, the metropolis is a difficult mess for the ordinary citizen. The Comptroller and Auditor General's (CAG) state audit report for the National Capital Territory (NCT) of Delhi government has unearthed a series of significant shortcoming...

-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...